Treatment options for patients with hepatocellular carcinoma are rapidly changing based on
positive results from phase 3 trials of targeted and immune-based therapies. More agents …

Hepatocellular carcinoma (HCC) is a highly prevalent, treatment-resistant malignancy with a
multifaceted molecular pathogenesis. Current evidence indicates that during …

Hypoxia unleashes the invasive and metastatic potential of tumor cells by largely unknown
mechanisms. The Met tyrosine kinase, a high affinity receptor for hepatocyte growth factor …

Hepatocellular carcinoma (HCC) is a significant cause of cancer-related morbidity and
mortality worldwide. Despite improvements in local therapies, including surgical resection …

Hepatocellular carcinoma (HCC) is a leading cause of death among cirrhotic patients and
has become a major health problem in developed countries. There is an elemental …

Dysregulation of pleiotropic growth factors, receptors and their downstream signaling
pathway components represent a central protumorigenic principle in human …

The c‐met proto‐oncogene encodes the tyrosine kinase receptor for hepatocyte growth
factor (HGF), a potent mitogen and motogen for epithelial cells. Because of its profound …

The tumor microenvironment has been largely studied as a dynamic system orchestrated by
inflammatory cells, including cancer cells, stroma as well as the extracellular matrix. It is …

Hepatocellular carcinoma (HCC) is the third cause of cancer‐related death worldwide.
Curative options for HCC are limited and exclusively available for patients carrying an early …

Hepatocellular carcinoma (HCC) is a leading cause of cancer-related death worldwide, and
its burden is expected to increase further in the next years. In spite of the advances of …